Leukocyte Attraction by CCL20 and Its Receptor CCR6 in Humans and Mice with Pneumococcal Meningitis by Klein, Matthias et al.
Leukocyte Attraction by CCL20 and Its Receptor CCR6 in
Humans and Mice with Pneumococcal Meningitis
Matthias Klein1*., Matthijs C. Brouwer2,3., Barbara Angele1, Madelijn Geldhoff2,3, Gabriel Marquez4,
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Abstract
We previously identified CCL20 as an early chemokine in the cerebrospinal fluid (CSF) of patients with pneumococcal
meningitis but its functional relevance was unknown. Here we studied the role of CCL20 and its receptor CCR6 in
pneumococcal meningitis. In a prospective nationwide study, CCL20 levels were significantly elevated in the CSF of patients
with pneumococcal meningitis and correlated with CSF leukocyte counts. CCR6-deficient mice with pneumococcal
meningitis and WT mice with pneumococcal meningitis treated with anti-CCL20 antibodies both had reduced CSF white
blood cell counts. The reduction in CSF pleocytosis was also accompanied by an increase in brain bacterial titers. Additional
in vitro experiments showed direct chemoattractant activity of CCL20 for granulocytes. In summary, our results identify the
CCL20-CCR6 axis as an essential component of the innate immune defense against pneumococcal meningitis, controlling
granulocyte recruitment.
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Introduction
Bacterial meningitis accounts for 135,000 deaths in 1.2 million
cases worldwide each year. Pneumococcal meningitis is the most
common and most severe form of meningitis: 16–35% of the
patients die and up to 50% of survivors suffer from long term
sequelae [1,2]. Animal experiments have elucidated the patho-
physiology of pneumococcal meningitis. Physiologically low
concentrations of leukocytes, antibodies, and complement com-
ponents in the subarachnoid space allow fast proliferation of
bacteria that have reached the subarachnoid space. Initially, the
infection is sensed by pathogen recognition receptors including
TLR2 and TLR4 [3,4]. Subsequently, a complex network of
cytokines and chemokines starts operating and leukocytes are
attracted [5,6]. Few of the cytokines and chemokines involved in
this network have been assigned a function and a role.
Using protein array technology we showed that the chemokine
CCL20 is up-regulated in the cerebrospinal fluid (CSF) of patients
with pneumococcal meningitis [7]. CCL20 is also known as
macrophage inflammatory protein 3a (MIP-3a), liver and action-
related chemokine (LARC), and Exodus-1 [8–10] and is expressed
in a broad spectrum of cell and tissue types [11]. In contrast to
other known chemokines that usually bind to multiple chemokine
receptors, CCL20 binds solely to the chemokine receptor CCR6,
and CCL20 is the only known cytokine ligand for CCR6. This
unique CCR6/CCL20 combination is involved in the chemoat-
traction of immature dendritic cells and effector/memory T- and
B-cells in skin and mucosal surfaces [11]. In addition to their
important role in autoinflammatory conditions such as inflamma-
tory bowel disease [12], psoriasis [13] or autoimmune encephalitis
(EAE) [14], CCL20 and CCR6 were detected in some bacterial
infections, e.g., parodontitis [15] and Helicobacter pylori gastritis
[16,17], and they were shown to play a role in the generation and
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maintenance of the adaptive immune defense against bacteria in
the gut [18]. In addition, CCR6 and CCL20 were found to be
crucial for the inflammatory response in a model of peritonitis
[19]. There have been no studies on the role of CCL20 and CCR6
in bacterial infections of the central nervous system.
Here, we assessed the role of CCL20 on cerebral inflammation
by determining CCL20 levels in the CSF of patients with
pneumococcal meningitis. As the infiltration of the subarachnoid
space is dominated by neutrophils during pneumococcal menin-
gitis, we next evaluated direct effects of CCL20 on neutrophil
recruitment in vitro and in vivo. Finally, the findings were validated
and explored in a well-established animal model of pneumococcal
meningitis by blocking CCL20 pharmacologically and by the
evaluation of CCR6-deficient mice.
Materials and Methods
All clinical investigations were conducted according to the
principles of the Declaration of Helsinki. Ethical approval was
obtained from the Medical Ethical Committee of the Academic
Medical Center, Amsterdam. Written informed consent was
obtained from all participating patients or their legally authorized
representatives. All animal experiments were approved by the
Government of Upper Bavaria.
Nationwide Prospective Community-acquired Bacterial
Meningitis Cohort
From March 2006 to June 2010 patients older than 16 years of
age with positive cerebrospinal fluid cultures who were identified
by The Netherlands Reference Laboratory for Bacterial Menin-
gitis were included in the study. Informed consent was obtained
from all participating patients or their legally authorized repre-
sentatives.
CSF Analysis
CSF of pneumococcal meningitis patients was obtained from
the diagnostic lumbar puncture. We selected 19 patients with
normal CSF who underwent CSF examination to exclude
subarachnoid hemorrhage and 24 patients with PCR proven viral
meningitis as controls. CSF was spun down and supernatant was
stored at 280uC until analysis. CSF CCL20 and IL-17 levels were
determined using the luminex technology using a Milliplex assay
(Millipore, Billerica, MA, USA) according to the manufacturer’s
instructions.
Experimental Pneumococcal Meningitis
A well-established mouse model of pneumococcal meningitis
was used as previously described [5]. Briefly, mice were weighed
and clinically examined by a clinical scoring system [5]. In healthy
Figure 1. In patients with acute bacterial meningitis, (A) CCL20 cerebrospinal fluid (CSF) levels were significantly elevated
compared with controls. CCL20 CSF levels of patients with pneumococcal meningitis correlated to (B) CSF white blood cell (WBC) counts, (C) CSF
blood glucose ratio, and (D) CSF protein levels (see text for details).
doi:10.1371/journal.pone.0093057.g001
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animals, the score was 0; infected animals that died within the
observation period scored 16 points. Meningitis was introduced by
transcutaneous injection of 15 ml of a bacterial suspension
containing 107 colony-forming units (cfu)/ml of Streptococcus
pneumoniae type D39 (S. pneumoniae, D39) into the cisterna magna
under short-term anesthesia with halothane. Then, animals were
allowed to wake up. All animals that were studied for longer than
24 h after infection received antibiotic therapy with ceftriaxone
100 mg/kg qd, starting 24 h after infection. At the end of each
experiment, the animals were weighed, scored clinically, and their
temperature was taken. Then, the mice were anesthetized with
100 mg/kg ketamine and 5 mg/kg xylazine and a catheter was
placed in the cisterna magna. Cerebrospinal fluid (CSF) samples
were obtained for CSF leukocyte count (CSF–WBC). After deep
anesthesia with ketamine, animals were killed using thiopental
(300 mg/kg body weight, intraperitoneal application) and per-
fused transcardially with 15 ml ice cold potassium buffered saline
(PBS) containing 10 U/ml heparin. The brain was removed and
frozen immediately. For the assessment of survival, humane
endpoints were used: animals that suffered from a clinical score .
14 points, status epilepticus, body temperature ,34uC or weight
loss .20% were euthanized using thiopenthal (300 mg/kg body
weight, intraperitoneal application). All animal experiments were
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, National Research Council, USA)
and with the German Animal Protection Act. All animal studies
were approved by the Committee on the Ethics of Animal
Experiments of the Government of Upper Bavaria, Germany
(Permit Numbers: 55.2-1-54-2531-32-04 and 55.2-1-54-2531-47-
08).
Experimental groups. (i) For analysis of time-dependent
CCL20 expression pattern, infected C57BL6 mice (Charles River)
were studied at the following time points: 6 h (n= 6), 24 h (n = 9),
30 h (n= 6), 48 h (n= 6), 72 h (n= 6), and 120 h after infection
(n = 7). (ii) To analyze the role of CCL20, C57BL/6 mice were
infected and intraperitoneally treated with a monoclonal anti-
CCL20 IgG antibody (R&D Systems, Cat.# MAB760) or IgG
isotype control antibody (R&D Systems, Cat.# MAB005) 3 hours
after infection (n= 10 per group). These mice were followed until
24 h after infection. (iii) For evaluation of the role of the receptor
CCR6 on the pathogenesis of pneumococcal meningitis, Ccr62/2
mice (backcrossed into C57BL/6 background for .8 generations)
[12,20] were infected and compared with infected wild type (WT)
control animals (C57BL/6). These animals were followed until
24 h (Ccr62/2 n= 12; WT n=12) and 48 h (Ccr62/2 n=12; WT
n=13) after infection. Ccr62/2 and WT mice were age- and sex-
matched. (iv) The impact of CCL20 on the recruitment of
leukocytes to the CSF in meningitis was evaluated by injection of
recombinant CCL20 (R&D Systems, Cat.# 760-M3-025/CF,
20 ng/mouse) or heat-inactivated recombinant CCL20 into the
cisterna magna of mice (n = 7) which were evaluated for CSF-
WBC 8 h after injection. Differential CSF white cell counts were
performed in 4 mice who received recombinant CCL20. In
addition, we tested the CCL20 chemotactic capacity in combina-
tion with pneumococcal antigens by injection of heat-killed
pneumococci and recombinant CCL20 (20 ng/mouse) or heat-
inactivated recombinant CCL20 (10 minutes, 85uC) into the
cisterna magna (n = 8) followed by determination of CSF-WBC
8 h after injection. (v) The possibility of a secondary IL-17
mediated pro-inflammatory effect of the CCL20/CCR6 axis was
evaluated by treating mice with anti-IL17 IgG antibody (100 mg
per mouse, R&D systems, Cat.# MAB421 [21]) or IgG2A isotype
control antibody (100 mg per mouse, R&D systems, Cat.#
MAB003) before infection; these mice were followed for 24 h
and 48 h (with antibacterial treatment at 24 h after infection). For
all experiments, animals that received an intracisternal injection of
sterile PBS were used as controls (uninfected controls).
Cerebellar bacterial titers. The cerebellum was dissected
and homogenized in 1 ml sterile PBS. Cerebellar homogenates
were diluted serially, plated on blood agar plates, and cultured for
24 h at 37uC with 5% CO2.
Analysis of cerebral bleeding and hydrocephalus. Mice
brains were cut in a frontal plane into 10 mm thick sections
throughout the ventricle system and photographed (9 sections with
Figure 2. CCL20 is expressed mainly during acute pneumococ-
cal meningitis. (A) Increased CCL20 levels were found in mice brain
homogenates during acute bacterial meningitis using ELISA. After
initiation of antibiotic therapy (starting 24 h after infection), they
decreased quickly to normal ((*) p,0.01 compared with uninfected
controls). In uninfected control mice, (B, C) only a very subtle CCL20-
positive staining was observed (white arrow). In contrast, in animals
with pneumococcal meningitis, CCL20-positive staining was found in
(D) epithel cells of the choroid plexus (black arrow) and (E) the
subarachnoid inflammatory infiltrate (#). Number of animals: 6 h: n = 6,
24 h: n = 9, 30 h: n = 6, 48 h: n = 6, 72 h: n = 6, and 120 h: n = 7.
Uninfected animals were used as controls (n = 11).
doi:10.1371/journal.pone.0093057.g002
CCL20 and CCR6 in Pneumococcal Meningitis
PLOS ONE | www.plosone.org 3 April 2014 | Volume 9 | Issue 4 | e93057
0.3 mm intervals). The brain and ventricle areas were measured
(Image tool, UTHSCSA) and the volumes were estimated (g
ventricle area/9 pictures60.3 mm). Haemorrhagic spots were
counted and the bleeding area was measured.
ELISA. Albumin content in brain homogenates was measured
by ELISA to assess blood-brain barrier integrity as previously
described [22]. Protein levels in mice brains for CCL20 (R&D
Systems, Cat.#MCC200), IL-1b, IL-6, and IL-17 as well as IL-22
in the CSF of mice were assessed by ELISA according to the
manufacturer’s instructions.
Immunohistochemistry
Paraffin-embedded brain tissue of infected and healthy control
mice was deparaffinized and boiled in 10 mM citrate buffer (pH 6)
in a microwave for antigen retrieval. Endogenous peroxidases
were blocked by incubation with 0.3% hydrogen peroxide in
methanol (MERCK, Hohenbrunn, Germany). Sections were
incubated with anti-CCL20 antibody (Abcam, Cambridge, UK,
ab9829) in blocking solution or (vi) with blocking solution without
primary antibody (negative control). Bound primary antibody was
detected using biotinylated goat anti-rabbit IgG (Vector Labs,
Burlingame, CA, USA) as well as streptavidin horseradish
peroxidase (DAKO, Hamburg, Germany) and diaminobenzidine
(Vector Labs, Burlingame, CA, USA), which yields a brown
reaction product. Counterstaining was performed using Mayer’s
hematoxylin.
Cell Culture
Hoxb8-immortalized neutrophil progenitors derived from
C57BL/6 mice [23,24] were cultured in Optimem medium
(Invitrogen) supplemented with 10% FCS, 30 mM b-mercapto-
ethanol (Sigma), P/S, 4% supernatant (SN) from stem cell factor
(SCF)-producing Chinese Hamster Ovarian cells, and 1 mM
oestrogen (Sigma). Neutrophil differentiation was induced by
removal of oestrogen, and subsequent culture for 4 days in
medium containing 2% SCF SN.
Flow Cytometric Analysis
Hoxb8 neutrophil suspensions with a cell concentration of
46106 cells/ml were incubated either with medium or with
10 ng/ml TNF-a for 20 min, as described in a recent study [25].
Then, cells were labeled with rat monoclonal antibodies directed
either against Gr-1 (conjugated with FITC), Mac-1 (conjugated
with PC7; both from eBioscience, San Diego, USA) or CCR6 (Rat
anti-mouse CCR6 IgG2a, conjugated with PE; from R&D
Systems) according to the manufacturer’s instructions. Appropri-
ate isotype antibodies served as controls. The samples were
analyzed using an FACS scan and Cell Quest Pro Software
(Becton Dickinson). Neutrophils were gated using their character-
istics in side and forward scatter. Their identity was further
confirmed by their GR-1 and Mac-1 signals. Results are expressed
as per cent positive cells in the appropriate gate. The markers were
set according to the IgG isotype controls. In selected experiments,
bone marrow-derived neutrophils were used instead of HoxB8
neutrophils. BMN were isolated as described previously with
minor modifications [26]. Briefly, bone marrow cells were flushed
from femurs with ice cold PBS containing 10% FCS. Neutrophils
were then isolated from the cell suspension by density gradient
centrifugation on Percoll (at 1,000 g for 30 min at 4uC). The
Percoll density gradient was prepared in a 15 ml tube by layering
4 ml of 57% Percoll solution on top of 4 ml of 80% Percoll
solution. The cell band that formed between the 81% and 57%
layer was harvested. Cells were diluted in Opti-Mem medium
containing 0.5% Nutridoma-SP (26106 cells/ml). The number
and purity of BMN were analyzed by a conventional smear with
Diffquick staining. BMN were then used for FACS analysis and
chemotaxis experiments as described.
Chemotaxis Assay
Neutrophil migration was assayed using a 48-well microche-
motaxis chamber (Neuroprobe, Bethesda, MD) [27]. Briefly,
CCL20, diluted in RPMI 1640, was placed in the lower well
(25 ml). HoxB8 neutrophils (26106 cells/ml) were added to the
upper well, which was separated from the lower well by a
Figure 3. Anti-CCL20 antibody therapy lowers CSF inflamma-
tion in vivo. Although blockage of CCL20 using an anti-CCL20
antibody was not reflected in clinical differences, it resulted (A) in a
decrease of CSF pleocytosis 24 h after infection. (B) This was associated
with increased brain bacterial titers. (C) Blood bacterial titers were not
affected. (*) p,0.05 compared with infected animals that received
control antibodies. AB= antibody. N= 10 per group.
doi:10.1371/journal.pone.0093057.g003
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micropore filter (pore sizes 5 mm). After 120 min, cells were fixed
with methanol and stained with DiffQuik (Baxter Diagnostics AG).
Chemotaxis was quantified by microscopic counting of cells that
migrated completely through the filter pores in 10 randomly
chosen high-power fields. Cell migration was expressed as the
mean number of leukocytes that migrated per field. FMLP was
used as a positive control at concentrations of 1026 M found to be
optimal for the migration of neutrophils.
Statistical Analysis
SYSTAT 9 (SPSS, Illinois, USA) was used for statistical
analysis. Student’s t-test was used for comparison of two
independent experimental groups at a certain time point unpaired.
Differences were considered significant at p,0.05. The Mann-
Whitney test with a-correction was used for evaluation of CCL20
expression at different time points. Data are expressed as mean 6
standard deviation.
Results
CCL20 during Acute Pneumococcal Meningitis in
Humans
To evaluate CCL20 during acute pneumococcal meningitis in
humans we used patients from a nationwide prospective cohort
study, performed from 2006–2010. In this study, 526 patients
(73%) suffered from S. pneumoniae meningitis, Neisseria meningitidis
was found in 90 (13%) episodes, Listeria monocytogenes in 35 (5%)
episodes, and others in 68 (9%) episodes [28]. CSF from diagnostic
lumbar puncture was available for 203 of 526 episodes of
pneumococcal meningitis (39%). We also selected 19 patients
with normal CSF who underwent CSF examination to exclude
subarachnoid hemorrhage and 24 patients with viral meningitis as
controls. In patients with pneumococcal meningitis, the median
CSF CCL20 concentration was 6.9 ng/ml (interquartile range
[IQR] 1.20–17.1). 96% of samples were above the lower limit of
detection (33 pg/ml). CCL20 levels in negative controls and
patients with viral meningitis were significantly lower than those of
bacterial meningitis patients (Figure 1A). CCL20 CSF levels were
correlated to CSF white blood cell (WBC) counts (Figure 1B,
Coefficient: 0.175, p = 0.019), CSF blood-glucose ratio (Figure 1C,
Figure 4. CCR6-deficient mice are more susceptible to pneumococcal meningitis. CCR6-deficient mice were more strongly affected from a
clinical perspective by infection with Streptococcus pneumoniae than wild type controls. This was reflected (A) in increased clinical scores and (B)
mortality. (C) CSF pleocytosis was lower in infected CCR6-deficient animals 24 h and 48 h after infection. (D) This was associated with higher brain
bacterial titers at the time of initiation of antibiotic therapy (24 h after infection). (*) p,0.05 compared with infected wild type animals. Number of
animals: 24 h: Ccr62/2 n= 12, WT n= 12; 48 h: Ccr62/2 n= 12, WT n= 13.
doi:10.1371/journal.pone.0093057.g004
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Coefficient:20.388, p,0.001), and CSF protein levels (Figure 1D,
Coefficient: 0.576, p,0.001).
Expression Profile of CCL20 in a Mouse Model of
Pneumococcal Meningitis
To confirm that CCL20 is expressed in the meningitis mouse
model, we examined mouse brain homogenates from WT mice
infected with S. pneumoniae. At 6 and 24 hours after infection,
CCL20 levels were increased (Figure 2A). At time points later than
48 h after infection, CCL20 levels had returned to normal. Low
concentrations of CCL20 were detected in uninfected animals
(Figure 2A). Immunohistochemical staining was positive for
CCL20 in the leukocyte infiltrate in the subarachnoid space and
in the plexus epithelium in mice subjected to pneumococcal
meningitis (Figures 2B–E). CCL20 staining was undetectable in
parenchymal cells (like migroglia) and within vessel walls.
CCL20 Blockage and CCR6 Deficiency Lead to a
Diminished Cerebral Immune Response and Poor
Outcome in Experimental Pneumococcal Meningitis
Then we aimed to decipher the functional role of CCL20 in our
well-established mouse model using anti-CCL20 antibodies and
CCR6-deficient mice. Treatment with anti-CCL20 antibodies
resulted in lower CSF-WBC counts (Figure 3A) and impaired
killing of bacteria compared to mice receiving isotype control
antibodies (Figure 3B). Clinical scores, brain volumes, and the
number of cerebral hemorrhages were similar in the investigated
groups (data not shown). Furthermore, no differences were
observed in blood-brain barrier damage, as well as brain IL-1b,
MIP-2 or IL-6 levels (data not shown).
CCR6 is the only currently known receptor for CCL20. Ccr62/
2 mice developed more severe disease than WT control animals
reflected by higher clinical scores 24 h after infection (Figure 4A)
and increased mortality 48 h after infection (Figure 4B). 24 h after
infection, Ccr62/2 mice had lower CSF-WBC counts (Figure 4C,)
and increased bacterial titers in the brain (Figure 4D). Brain IL-6,
IL-1b, and MIP-2 levels of Ccr62/2 mice and WT mice were
similar at 24 h (data not shown). At 48 h after infection, Ccr62/2
mice had lower CSF-WBC counts (Figure 4C), but increased brain
volumes (Figure 5A) and an increased blood-brain barrier
breakdown (Figure 5B) compared to infected WT mice. At 48 h
after infection, bacterial titers (Figure 4D) and the number of
cerebral bleedings in Ccr62/2 and WT mice were similar (Figure 5
C–F). In summary, Ccr62/2 mice suffering from meningitis were
affected more strongly than wild type mice, as evidenced by an
increase in clinical score and increased mortality.
The CCL20-CCR6 Axis has a Chemoattractant Function
To test a direct function of CCR6/CCL20 on mouse
neutrophils, we used an in vitro system where neutrophils can be
differentiated from HoxB8-transformed progenitors [23]. In vitro,
undifferentiated precursor cells (data not shown) and differentiated
(Gr1-positive) neutrophils were found to express CCR6 (Figure 6A
and B). The CCR6 expression on differentiated Gr1-positive
neutrophils increased after stimulation with TNF-a (Figure 6C and
D). Whereas unstimulated neutrophils derived from the bone
marrow of C57BL/6 mice were CCR6-negative (Figure 6E and
F), CCR6 was found on these cells upon exposure to HKP
(Figure 6G and H). This expression increased in a time-dependent
fashion (data not shown). Using a chemotaxis assay, we found that
both HoxB8 neutrophils and bone marrow-derived neutrophils
migrated towards CCL20 in a dose-dependent manner (Figure 6I
and K). In vivo, recombinant CCL20 amplified the CSF pleocytosis
elicited by heat-killed pneumococci 8 h after infection (Figure 6I).
Also, intracisternally applied CCL20 alone (without heat-killed
pneumococci) had a mild chemotactic activity because CSF
pleocytosis was significantly increased as compared with animals
that received an intracisternal injection of heat inactivated CCL20
(Figure 6L). CCL20 mainly attracted granulocytes as differential
CSF white cell counts revealed 72613% granulocytes, 1969%
lymphocytes, and 963% monocytes.
The Chemoattractant Activity of CCL20 is Independent of
IL-17A/F and IL-22
Several reports have suggested that CCL20 leads to recruitment
of CCR6-positive Th17 cells [29]. Th17 cells are potentially
important for the initiation of early inflammation by the
production of IL-17 or IL-22 [30]. To evaluate the influence of
IL-17 in patients with pneumococcal meningitis we measured CSF
levels of IL-17 in 203 patients and 42 controls. IL-17 was up-
regulated in the CSF of patients with bacterial meningitis
compared to controls (Figure 7A), but CSF IL-17 levels did not
correlate with CSF-WBC counts (r =20.049, p = 0.513). In WT
mice with pneumococcal meningitis, IL-17 expression was higher
than in uninfected wild type controls (Figure 7B). However,
blockage of the heterodimer IL-17A/F by antibody treatment did
not reduce inflammation 24 h and 48 h after infection (Figure 7C).
Thus, IL-17A/F seems unlikely to be involved in the chemoat-
Figure 5. CCR6-deficient mice suffer from increased brain
edema after antibiotic therapy. (A) Infected mice with CCR6-
deficiency developed more pronounced brain edema than infected wild
type mice 48 h after infection, reflected in an increase in the estimated
brain volume. (B) At the same time point, an increase of brain albumin
content was noted in infected Ccr62/2 mice, indicating blood-brain
barrier disruption. These differences were only seen after but not before
initiation of antibiotic therapy (24 h after infection). (C–G) Intracranial
bleeding was similar in infected Ccr62/2 and wild type mice. (*) p,0.05
compared with WT control animals. Number of animals: 24 h: Ccr62/2
n= 12, WT n=12; 48 h: Ccr62/2 n= 12, WT n= 13.
doi:10.1371/journal.pone.0093057.g005
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tractant activity of the CCL20/CCR6 axis during pneumococcal
meningitis.
Furthermore, we determined IL-22 concentrations in murine
brains in order to gain insight into its possible involvement in the
biological activity of the CCL20/CCR6 axis. IL-22 was elevated
in brains of mice with pneumococcal meningitis as compared with
uninfected controls at 24 h after infection (uninfected controls vs.
infected wild type mice: 1.8260.29 pg/mg brain protein vs.
Figure 6. CCL20 chemoattracts granulocytes in vitro and in vivo. HoxB8 precursor cells could be differentiated into neutrophils, as indicated
by the expression of Gr1. (A, B) The differentiated neutrophils were CCR6 positive. (C, D) Stimulation with TNF-a led to a marked increase of CCR6
expression in differentiated Hoxb8 neutrophils. Whereas (E, F) unstimulated bone marrow-derived neutrophils were CCR6-negative, (G, H) CCR6
became detectable on these cells upon exposure to heat-killed pneumococci (HKP). Using a chemotaxis assay, (I) differentiated Hoxb8 neutrophils
and (K) bone marrow derived neutrophils migrated towards CCL20 in a dose-dependent way, demonstrating an in vitro chemotactic effect of CCL20
protein on CCR6 positive granulocytes. FMLP and CXCL2 were used as positive controls. (*) p,0.05 compared with Hoxb8 exposed to medium. (H)
After intrathecal injection of recombinant CCL20 (rCCL20, n = 7) in wild type mice, a chemotactic effect was seen in comparison to injection with heat
inactivated rCCL20 (rCCL20i, control, n = 7). In addition, rCCL20 co-administration to HKP led to a significant increase of the CSF-pleocytosis compared
with rCCL20i co-administration to HKP (n = 8 for each group). (*) p,0.05 compared with rCCL20i or HKP+rCCL20i respectively.
doi:10.1371/journal.pone.0093057.g006
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4.0861.51 pg/mg brain protein, p,0.001) and 48 h after
infection (uninfected controls vs. infected wild type mice:
1.3760.19 pg/mg brain protein vs. 3.1561.78 pg/mg brain
protein, p = 0.012). However, we did not detect any differences
in IL22 levels between infected WT and CCR62/2 mice at 24 h
after infection (infected wild type mice vs. infected CCR62/2
mice: 4.0861.51 pg/mg brain protein vs. 3.3961.84 pg/mg brain
protein, p = 0.37) or at 48 h after infection (infected wild type mice
vs. infected CCR62/2 mice: 3.1561.78 pg/mg brain protein vs.
2.5960.59 pg/mg brain protein, p = 0.74). This observation
argues against an essential role of IL-22 as a downstream mediator
of CCL20/CCR6-induced pleocytosis.
Discussion
Our results identify the CCL20-CCR6 axis as an important
component of the innate immune defense against pneumococcal
meningitis, controlling leukocyte recruitment and leukocyte-
mediated bacterial killing in an IL17-independent manner.
The hallmark of pneumococcal meningitis is severe inflamma-
tion of the meninges and the subarachnoid space [31]. The
inflammatory response is initiated and maintained by the
expression of multiple cytokines such as Il-1b, KC, and MIP-2
[5]. High levels of CCL20 in the CSF of humans have been
detected by protein array technology in patients with acute
pneumococcal meningitis but not in control patients or in patients
after recovery [7]. Here, the semi-quantitative protein array data
was confirmed by quantitative analysis using a Luminex assay,
which showed markedly enhanced levels of CCL20 in the CSF of
pneumococcal meningitis patients included in a large prospective
cohort study [32].
Time course analysis in a well-established mouse model of
pneumococcal meningitis demonstrated that CCL20 was exclu-
sively up-regulated during the acute stage and levels returned to
normal quickly after administration of antibiotic therapy. CCL20
has recently also been shown to be produced in response to other
bacterial infections. For example, CCL20 was detected in the
gastric tissue of patients with H. pylori infection, and challenge of
gastric epithelial cell lines with H. pylori induced the expression of
CCL20 [16,33]. This expression was triggered by the activation of
NF-kappa B. Furthermore, in vitro CCL20 production was found
in response to Pam3CSK4, interacting with TLR2, and LPS,
interacting with TLR4 [34,35]. Previously, we have demonstrated
that pneumococcal challenge of the central nervous system
activates the innate immune system via TLR2 and TLR4 and
leads to an activation of NF-kappa B [4]. Thus, it appears possible
that expression of CCL20 is mediated by TLR2 and TLR4
activation during pneumococcal meningitis.
Using a mouse model of pneumococcal meningitis, we could
demonstrate a significant function of CCL20 and CCR6 in
pneumococcal meningitis: whenever the CCL20-CCR6 axis was
disabled, either by blockage of CCL20 using an anti-CCL20
antibody or by using CCR6-deficient mice, we noted a significant
reduction of the CSF pleocytosis. This suggested a role of CCL20
in the recruitment of leukocytes in response to pneumococci.
Chemotactic properties of CCL20 have previously been observed
in vitro for mononuclear cells, T-cells [17,36], and dendritic cells
[37]. Also, neutrophils isolated from humans have been shown to
express CCR6 and migrate towards CCL20 [38]. In vivo, a
chemotactic effect of the CCL20/CCR6 axis has been demon-
strated in diseases such as rheumatoid arthritis and autoimmune
encephalitis. In vivo studies on bacterial infections have, so far, been
limited to a description of an increase of CCL20 and CCR6-
positive cells at the site of infection [15–17,33,39]. A significant
functional role of CCR6 has only been shown for macrophage
attraction and subsequent T-cell activation in response to skin
infection of mice with Salmonella species [40]. Furthermore, the
immune response was diminished in mice lacking CCR6 when
multimicrobial peritonitis was induced by cecal ligation and
puncture [19]. Further functional data on the recruitment of
neutrophils by CCL20 and CCR6 during acute bacterial
infections are sparse. Here, we first confirmed in vitro that
neutrophils (MAC-1 positive cells differentiated from progenitors)
express CCR6 and migrate towards CCL20, suggesting a direct
chemotactic effect of CCL20 in neutrophil recruitment. Then, we
demonstrated that, in mice, intercisternal administration of
CCL20 by itself results in leukocyte recruitment into the CSF
and also enhances CSF pleocytosis elicited by intrathecal injection
of pneumococcal components (heat-inactivated pneumococci).
Combined with the observation that blockage of CCL20 and
deficiency of CCR6 reduced CSF pleocytosis after intracisternal
pneumococcal challenge, our data indicate a crucial role of
CCL20 in the recruitment of granulocytes to the subarachnoid
space during pneumococcal meningitis. Since [i] CCL20 attracts
granulocytes in a Boyden chamber assay and [ii] intracisternal CCL20
injection leads to CSF pleocytosis with granulocytes as the
predominant cell type, we postulate a direct chemotactic role of
CCL20 in the recruitment of granulocytes in pneumococcal
meningitis. However, CCL20 might also contribute to granulocyte
invasion into the CSF indirectly by attracting and/or activating
Figure 7. The pro-inflammatory effect of the CCL20/CCR6 axis seems independent of IL-17 production. IL17 was up-regulated in the
CSF of (A) humans and (B) mice with pneumococcal meningitis. (C) However, antibody blockage of IL-17 in experimental pneumococcal meningitis
did not lead to a reduction of inflammation in the CSF. P,0.05 as compared with uninfected controls. Number of animals: n = 5 mice per group.
doi:10.1371/journal.pone.0093057.g007
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other cell types that in turn promote granulocyte immigration into
the subarachnoid space.
Several reports have suggested that CCL20 leads to recruitment
of CCR6-positive Th17 cells. Th17 cells are the main producers of
IL-17 which in turn has been found to be elevated in children with
bacterial meningitis and a pro-inflammatory role was postulated
[41]. Here, we could show an elevation of IL-17 in pneumococcal
meningitis in adults, but we did not find a correlation of IL-17
levels and CSF-WBC. Furthermore, blockage of IL-17 in the
experimental meningitis model did not diminish the immune
response. Thus, IL-17 does not seem to mediate the pro-
inflammatory effect of the CCL20/CCR6 axis in pneumococcal
meningitis. Also, Th17 cells are known to produce IL-22.
However, elevated IL-22 levels were not altered in CCR6-
deficient mice in comparison to infected wild type mice. This
missing difference in brain IL-22 levels argues against a critical
role of this TH17-cytokine as a downstream mediator of CCL20/
CCR6-induced leukocyte recruitment to the CSF in pneumococ-
cal meningitis.
So far, CCL20 is the only known chemokine ligand of CCR6
[42]. Blocking CCL20 by antibodies was less effective than using
CCR6-deficient animals in terms of the clinical course of the
disease. Most likely, this might be explained by a generally less
powerful impact of using functionally blocking antibodies in vivo in
comparison with using genetically modified animals. Alternatively,
other, as yet undetermined chemokine ligands or non-chemokine
ligands of CCR6 like some b-defensins [43] could contribute to
CCR6-mediated effects in meningitis and explain this discrepancy.
At the time when antibiotic therapy was started, we found
significantly higher bacterial loads in infected Ccr62/2 mice than
in infected WT mice. This phenomenon can be explained by
decreased bacterial killing due to insufficient attraction of
granulocytes. Similarly, infected mice lacking MyD88 or TLR2
and TLR4 (who also have an impaired immune response that
manifests in a diminished CSF pleocytosis) are known to suffer
from higher bacterial brain titers [4,22]. Another explanation for
the increase of bacterial titers after capture of CCL20 could be the
previously described antibacterial property of CCL20 [44] but,
in vitro, incubation of D39 with CCL20 did not reduce pneumo-
coccal growth (data not shown). Thus, an antibacterial effect of
CCL20 on S. pneumoniae does not seem to play a role in
pneumococcal meningitis.
The higher numbers of S. pneumoniae D39 in Ccr62/2 mice
might be the reason for the more pronounced clinical deteriora-
tion after antibiotic therapy. S. pneumoniae D39 is a potent inducer
of cell death, pneumolysin being identified as one pneumococcal
toxin that mediates such damage. For example, previous reports
demonstrated reduced endothelial damage upon exposure to
pneumolysin-deficient bacteria, as compared to the wild type
strain [45,46]. In vivo, higher bacterial titers lead to higher levels of
pneumolysin, which is released especially after initiation of
pneumococcal killing by antibiotic therapy [47]. Here, clinical
deterioration after antibiotic therapy was associated with an
elevation of blood-brain barrier breaching and brain edema. In
consequence, the poor outcome in infected Ccr62/2 mice after
antibiotic therapy can most likely be attributed to the increase of
bacterial outgrowth, resulting in higher pneumolysin levels and
more pronounced cell damage.
In conclusion, CCL20 was shown to be a crucial chemotactic
chemokine during acute pneumococcal meningitis, attracting
neutrophils to the subarachnoid space. The neutrophil response
in pneumococcal meningitis that is guided to the subarachnoid
space through the chemokine/receptor pair CCL20/CCR6 is
important for limiting bacterial outgrowth.
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